Anya M. Litvak, MD, Paul K. Paik, MD, Kaitlin M. Woo, MS, Camelia S

Slides:



Advertisements
Similar presentations
Su K. Metcalfe, MD, MPH, Michael T
Advertisements

Unique Genetic and Survival Characteristics of Invasive Mucinous Adenocarcinoma of the Lung  Hyo Sup Shim, MD, PhD, Mari- Kenudson, MD, Zongli Zheng,
Comprehensive Pathological Analyses in Lung Squamous Cell Carcinoma: Single Cell Invasion, Nuclear Diameter, and Tumor Budding Are Independent Prognostic.
Disparities in Treatment of Patients with Inoperable Stage I Non–Small Cell Lung Cancer: A Population-Based Analysis  Matthew Koshy, MD, Renuka Malik,
Role of Postoperative Radiotherapy in Pathologic Stage IIIA (N2) Non–Small Cell Lung Cancer in a Prospective Nationwide Oncology Outcomes Database  Alex.
The BIM Deletion Polymorphism and its Clinical Implication in Patients with EGFR- Mutant Non–Small-Cell Lung Cancer Treated with EGFR Tyrosine Kinase Inhibitors 
Role of Postoperative Radiotherapy in Pathologic Stage IIIA (N2) Non–Small Cell Lung Cancer in a Prospective Nationwide Oncology Outcomes Database  Alex.
APLCC ORAL ABSTRACT SESSIONS - MONDAY, NOVEMBER 26
Nicolas Girard, MD, Julie Teruya-Feldstein, MD, Eden C
Susan C. Scott, MD, Nathan A. Pennell, MD, PhD 
Tetsuya Mitsudomi, MD, Hirohito Tada, MD  Journal of Thoracic Oncology 
Outcomes of unexpected pathologic N1 and N2 disease after video-assisted thoracic surgery lobectomy for clinical stage I non–small cell lung cancer  Hong.
The IASLC Lung Cancer Staging Project: The New Database to Inform the Eighth Edition of the TNM Classification of Lung Cancer  Ramón Rami-Porta, MD, FETCS,
Electronic Updates for JTO Readers
Geoffrey R. Oxnard, MD, Vincent A. Miller, MD, Mark E
Epidermal Growth Factor Receptor Mutations in 510 Finnish Non–Small-Cell Lung Cancer Patients  Satu Mäki-Nevala, MSc, Mikko Rönty, MD, Mike Morel, MBiolSci,
Treatment and Prognosis of Isolated Local Relapse after Stereotactic Body Radiotherapy for Clinical Stage I Non-Small-Cell Lung Cancer  Masatsugu Hamaji,
Unique Genetic and Survival Characteristics of Invasive Mucinous Adenocarcinoma of the Lung  Hyo Sup Shim, MD, PhD, Mari- Kenudson, MD, Zongli Zheng,
Central versus Peripheral Tumor Location: Influence on Survival, Local Control, and Toxicity Following Stereotactic Body Radiotherapy for Primary Non–Small-Cell.
Phase II Trial of Paclitaxel and Cisplatin in Patients with Extensive Stage Small Cell Lung Cancer: Cancer and Leukemia Group B Trial 9430  Thomas E.
Telomere Length and Recurrence Risk after Curative Resection in Patients with Early- Stage Non–Small-Cell Lung Cancer: A Prospective Cohort Study  Eric.
The Influence of the Evolution of First-Line Chemotherapy on Steadily Improving Survival in Advanced Non-Small-Cell Lung Cancer Clinical Trials  Krista.
Patterns of survival and recurrence after surgical treatment of early stage non–small cell lung carcinoma in the ACOSOG Z0030 (ALLIANCE) trial  Stacey.
Distinct Clinical Course of EGFR-Mutant Resected Lung Cancers: Results of Testing of 1118 Surgical Specimens and Effects of Adjuvant Gefitinib and Erlotinib 
Phase II Trial of Carboplatin, Paclitaxel, Cetuximab, and Bevacizumab Followed by Cetuximab and Bevacizumab in Advanced Nonsquamous Non–Small-Cell Lung.
Mediastinal Lymph Node Examination and Survival in Resected Early-Stage Non– Small-Cell Lung Cancer in the Surveillance, Epidemiology, and End Results.
Meta-Analysis of First-Line Therapies in Advanced Non–Small-Cell Lung Cancer Harboring EGFR-Activating Mutations  Benjamin Haaland, PhD, Pui San Tan,
Intratumoral Lymphatic Vessel Involvement is an Invasive Indicator of Completely Resected Pathologic Stage I Non-small Cell Lung Cancer  Masahiko Harada,
Clinical Characteristics and Outcomes for Patients With Thymic Carcinoma: Evaluation of Masaoka Staging  Anya M. Litvak, MD, Kaitlin Woo, MS, Sara Hayes,
Effects of Chemotherapy on Survival of Elderly Patients with Small-Cell Lung Cancer: Analysis of the SEER-Medicare Database  Laura C. Caprario, MD, MS,
Erik Jakobsen, Maria Iachina, Karen Ege Olsen, Anders Green 
Ellen Kim, MD, MPH, Siran Koroukian, PhD, Charles R. Thomas, MD 
Socioeconomic Status Is Associated with Depressive Severity Among Patients with Advanced Non–Small-Cell Lung Cancer: Treatment Setting and Minority Status.
The Prognostic Impact of KRAS, Its Codon and Amino Acid Specific Mutations, on Survival in Resected Stage I Lung Adenocarcinoma  Benjamin Izar, MD, PhD,
Strategies to Improve Outcomes of Patients with EGFR-Mutant Non–Small Cell Lung Cancer: Review of the Literature  Caicun Zhou, MD, PhD, Luan Di Yao, MD 
Impact on Disease-Free Survival of Adjuvant Erlotinib or Gefitinib in Patients with Resected Lung Adenocarcinomas that Harbor EGFR Mutations  Yelena Y.
Re-evaluation of the Role of Postoperative Radiotherapy and the Impact of Radiation Dose for Non–Small-Cell Lung Cancer Using the National Cancer Database 
Daniel Morgensztern, MD, Boone Goodgame, MD, Maria Q
Impact of positive pleural lavage cytology on survival in patients having lung resection for non–small-cell lung cancer: An international individual patient.
Differences in Patterns of Recurrence in Early-Stage Versus Locally Advanced Non- Small Cell Lung Cancer  Feiran Lou, MD, MS, Camelia S. Sima, MD, MS,
Patterns of Disease Recurrence after SABR for Early Stage Non–Small-Cell Lung Cancer: Optimizing Follow-Up Schedules for Salvage Therapy  Naomi E. Verstegen,
Erratum Journal of Thoracic Oncology
Onkar V. Khullar, MD, Yuan Liu, PhD, Theresa Gillespie, PhD, Kristin A
Elizabeth Cathcart-Rake, MD, Ariel Lopez-Chavez, MD, MS 
Neutrophil–Lymphocyte and Platelet–Lymphocyte Ratios as Prognostic Factors after Stereotactic Radiation Therapy for Early-Stage Non–Small-Cell Lung Cancer 
A Prospective Study of Tumor Suppressor Gene Methylation as a Prognostic Biomarker in Surgically Resected Stage I to IIIA Non–Small-Cell Lung Cancers 
Mitotic Inhibitors Journal of Thoracic Oncology
Prognostic Impact of Immune Microenvironment in Lung Squamous Cell Carcinoma  Kyuichi Kadota, MD, PhD, Jun-ichi Nitadori, MD, PhD, Hideki Ujiie, MD, Daniel.
MET Expression Plays Differing Roles in Non–Small-Cell Lung Cancer Patients with or without EGFR Mutation  Ling Huang, MS, She-Juan An, PhD, Zhi-Hong.
Mirror Mirror on the Wall, Who Is the Fairest of Them All
EGFR delE709_T710insD: A Rare but Potentially EGFR Inhibitor Responsive Mutation in Non–Small-Cell Lung Cancer  Allison Ackerman, MD, Michael A. Goldstein,
EGFR Mutation and Brain Metastasis in Pulmonary Adenocarcinomas
DHA-Paclitaxel (Taxoprexin) as First-Line Treatment in Patients with Stage IIIB or IV Non-small Cell Lung Cancer: Report of a Phase II Open-Label Multicenter.
PTEN and PIK3CA Expression Is Associated with Prolonged Survival after Gefitinib Treatment in EGFR-Mutated Lung Cancer Patients  Hideki Endoh, MD, PhD,
Role of Postoperative Radiotherapy in Nonlocalized Thymoma
Conditional Survival of Malignant Thymoma Using National Population-Based Surveillance, Epidemiology, and End Results (SEER) Registry (1973–2011)  Ellen.
Multi-institutional Oncogenic Driver Mutation Analysis in Lung Adenocarcinoma: The Lung Cancer Mutation Consortium Experience  Lynette M. Sholl, MD, Dara.
Immune-Modulating Vaccines in Non-small Cell Lung Cancer
Maintenance Therapy and Advanced Non–Small-Cell Lung Cancer: A Skeptic's View  Martin J. Edelman, MD, Thierry Le Chevalier, MD, Jean-Charles Soria, MD,
Bolstering the Case for Lobectomy in Stages I, II, and IIIA Small-Cell Lung Cancer Using the National Cancer Data Base  Susan E. Combs, MA, Jacquelyn.
Jie Huang, Juan Peng, Linlang Guo, MD, PhD 
Phase II Trial of Neoadjuvant Bevacizumab Plus Chemotherapy and Adjuvant Bevacizumab in Patients with Resectable Nonsquamous Non–Small-Cell Lung Cancers 
Wedge Resection for Non-small Cell Lung Cancer in Patients with Pulmonary Insufficiency: Prospective Ten-Year Survival  John P. Griffin, MD, Charles E.
Christina S. Baik, MD, MPH, Marc C. Chamberlain, MD, Laura Q. Chow, MD 
APLCC POSTER SESSION 2 - WEDNESDAY, NOVEMBER 28
Jamie E. Chaft, MD, Camelia S. Sima, MD, MS, Michelle S
Phase I Study of Induction Chemotherapy and Concomitant Chemoradiotherapy with Irinotecan, Carboplatin, and Paclitaxel for Stage III Non-small Cell Lung.
Effect of Tumor Size on Prognosis in Patients Treated with Radical Radiotherapy or Chemoradiotherapy for Non–Small Cell Lung Cancer: An Analysis of the.
Prognostic Significance of Tumor Size in Patients with Stage III Non–Small-Cell Lung Cancer: A Surveillance, Epidemiology, and End Results (SEER) Survey.
Reply to “Influence of Body Mass Index on Overall Survival Following Surgical Resection of Non–Small Cell Lung Cancer: Methodological Issues”  Boris Sepesi,
Presentation transcript:

Clinical Characteristics and Course of 63 Patients with BRAF Mutant Lung Cancers  Anya M. Litvak, MD, Paul K. Paik, MD, Kaitlin M. Woo, MS, Camelia S. Sima, MD, Matthew D. Hellmann, MD, Maria E. Arcila, MD, Marc Ladanyi, MD, PhD, Charles M. Rudin, MD, PhD, Mark G. Kris, MD, Gregory J. Riely, MD, PhD  Journal of Thoracic Oncology  Volume 9, Issue 11, Pages 1669-1674 (November 2014) DOI: 10.1097/JTO.0000000000000344 Copyright © 2014 International Association for the Study of Lung Cancer Terms and Conditions

FIGURE 1 Frequency of BRAF mutations in non–small-cell lung cancer (NSLCC). A, Stages I–IIIa, n = 32. B, Stage IIIb/IV, n = 31. Journal of Thoracic Oncology 2014 9, 1669-1674DOI: (10.1097/JTO.0000000000000344) Copyright © 2014 International Association for the Study of Lung Cancer Terms and Conditions

FIGURE 2 Overall Survival of BRAF Mutant Lung Cancer. A, Stage I–IIIa resected lung cancers. Three patients with early-stage disease were excluded from the analysis because resection was not performed. B, Stage IIIb–IV lung cancers. Four patients were excluded from the analysis because molecular testing was performed after the date of last follow-up. Journal of Thoracic Oncology 2014 9, 1669-1674DOI: (10.1097/JTO.0000000000000344) Copyright © 2014 International Association for the Study of Lung Cancer Terms and Conditions

FIGURE 3 Overall survival of BRAF V600 vs other lung adenocarcinoma genotypes. A, Stage I -IIIa resected lung cancers. One patient with early-stage BRAF-V600 lung cancer was excluded from the analysis as resection was not performed. (BRAF V600 vs. EGFR: p=0.48; BRAF V600 vs. KRAS: p=0.88; EGFR vs. KRAS: p=0.093) B, Stage IIIb -IV unresected lung cancers. Two patients with BRAF-V600 lung cancers were excluded from the analysis as molecular testing was performed after the date of last follow-up. (BRAF V600 vs. EGFR: p=0.25; BRAF V600 vs. KRAS: p=0.12; EGFR vs. KRAS: p <0.001). Journal of Thoracic Oncology 2014 9, 1669-1674DOI: (10.1097/JTO.0000000000000344) Copyright © 2014 International Association for the Study of Lung Cancer Terms and Conditions